Skip to main content

Advertisement

SpringerLink
Log in

Contemporary Controversies in Digoxin Use in Systolic Heart Failure

  • Pharmacologic Therapy (W H W Tang, Section Editor)
  • Published:
Current Heart Failure Reports Aims and scope Submit manuscript

Abstract

Digoxin remains one of the oldest therapies for heart failure; however, its safety and efficacy have been controversial since its initial use. Questions that remain include the clinical efficacy of digoxin when added to contemporary medical therapy, when and if it should be added, and how to minimize adverse effects. In this review, we will summarize recent data on the use of digoxin in systolic heart failure and address some of the controversies regarding the role of digoxin in the modern era of heart failure treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. W W. An account of the foxglove, and some of its medical uses: with practical remarks on dropsy, and other diseases. Birmingham, England: M Swinney 1785.

  2. Digitalis Investigation G. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525–33.

    Article  Google Scholar 

  3. Smith TW, Antman EM, Friedman PL, Blatt CM, Marsh JD. Digitalis glycosides: mechanisms and manifestations of toxicity. Part I. Prog Cardiovasc Dis. 1984;26:413–58.

    Article  CAS  PubMed  Google Scholar 

  4. Smith TW, Antman EM, Friedman PL, Blatt CM, Marsh JD. Digitalis glycosides: mechanisms and manifestations of toxicity. Part II. Prog Cardiovasc Dis. 1984;26:495–540.

    Article  CAS  PubMed  Google Scholar 

  5. Smith TW, Antman EM, Friedman PL, Blatt CM, Marsh JD. Digitalis glycosides: mechanisms and manifestations of toxicity. Part III. Prog Cardiovasc Dis. 1984;27:21–56.

    Article  CAS  PubMed  Google Scholar 

  6. Gheorghiade M, St Clair J, St Clair C, Beller GA. Hemodynamic effects of intravenous digoxin in patients with severe heart failure initially treated with diuretics and vasodilators. J Am Coll Cardiol. 1987;9:849–57.

    Article  CAS  PubMed  Google Scholar 

  7. Gheorghiade M, Hall V, Lakier JB, Goldstein S. Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combinations in patients with severe heart failure. J Am Coll Cardiol. 1989;13:134–42.

    Article  CAS  PubMed  Google Scholar 

  8. Ribner HS, Plucinski DA, Hsieh AM, et al. Acute effects of digoxin on total systemic vascular resistance in congestive heart failure due to dilated cardiomyopathy: a hemodynamic-hormonal study. Am J Cardiol. 1985;56:896–904.

    Article  CAS  PubMed  Google Scholar 

  9. Arnott WM, Withering W. Physiologic problems in mitral stenosis. Am Heart J. 1964;68:145–8.

    Article  CAS  PubMed  Google Scholar 

  10. Guyatt GH, Sullivan MJ, Fallen EL, et al. A controlled trial of digoxin in congestive heart failure. Am J Cardiol. 1988;61:371–5.

    Article  CAS  PubMed  Google Scholar 

  11. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol. 1993;22:955–62.

    Article  CAS  PubMed  Google Scholar 

  12. Sullivan M, Atwood JE, Myers J, et al. Increased exercise capacity after digoxin administration in patients with heart failure. J Am Coll Cardiol. 1989;13:1138–43.

    Article  CAS  PubMed  Google Scholar 

  13. Gheorghiade M, Hall VB, Jacobsen G, Alam M, Rosman H, Goldstein S. Effects of increasing maintenance dose of digoxin on left ventricular function and neurohormones in patients with chronic heart failure treated with diuretics and angiotensin-converting enzyme inhibitors. Circulation. 1995;92:1801–7.

    Article  CAS  PubMed  Google Scholar 

  14. Slatton ML, Irani WN, Hall SA, et al. Does digoxin provide additional hemodynamic and autonomic benefit at higher doses in patients with mild to moderate heart failure and normal sinus rhythm? J Am Coll Cardiol. 1997;29:1206–13.

    Article  CAS  PubMed  Google Scholar 

  15. Krum H, Bigger Jr JT, Goldsmith RL, Packer M. Effect of long-term digoxin therapy on autonomic function in patients with chronic heart failure. J Am Coll Cardiol. 1995;25:289–94.

    Article  CAS  PubMed  Google Scholar 

  16. van Veldhuisen DJ, Brouwer J, Man in ’t Veld AJ, Dunselman PH, Boomsma F, Lie KI. Progression of mild untreated heart failure during six months follow-up and clinical and neurohumoral effects of ibopamine and digoxin as monotherapy. DIMT Study Group. Dutch Ibopamine Multicenter Trial. Am J Cardiol. 1995;75:796–800.

    Article  PubMed  Google Scholar 

  17. Lee DC, Johnson RA, Bingham JB, et al. Heart failure in outpatients: a randomized trial of digoxin versus placebo. N Engl J Med. 1982;306:699–705.

    Article  CAS  PubMed  Google Scholar 

  18. van Veldhuisen DJ, Man in ’t Veld AJ, Dunselman PH, et al. Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT). J Am Coll Cardiol. 1993;22:1564–73.

    Article  PubMed  Google Scholar 

  19. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147–239.

    Article  PubMed  Google Scholar 

  20. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14:803–69.

    Article  CAS  PubMed  Google Scholar 

  21. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289:871–8.

    Article  CAS  PubMed  Google Scholar 

  22. Goldberger ZD, Goldberger AL. Therapeutic ranges of serum digoxin concentrations in patients with heart failure. Am J Cardiol. 2012;109:1818–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J. 2006;27:178–86.

    Article  CAS  PubMed  Google Scholar 

  24. Jelliffe RW, Brooker G. A nomogram for digoxin therapy. Am J Med. 1974;57:63–8.

    Article  CAS  PubMed  Google Scholar 

  25. Koup JR, Greenblatt DJ, Jusko WJ, Smith TW, Koch-Weser J. Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses. J Pharmacokinet Biopharm. 1975;3:181–92.

    Article  CAS  PubMed  Google Scholar 

  26. Jusko WJ, Szefler SJ, Goldfarb AL. Pharmacokinetic design of digoxin dosage regimens in relation to renal function. J Clin Pharmacol. 1974;14:525–35.

    Article  CAS  PubMed  Google Scholar 

  27. Bauman JL, DiDomenico RJ, Viana M, Fitch M. A method of determining the dose of digoxin for heart failure in the modern era. Arch Intern Med. 2006;166:2539–45.

    Article  CAS  PubMed  Google Scholar 

  28. DiDomenico RJ, Bress AP, Na-Thalang K, et al. Use of a simplified nomogram to individualize digoxin dosing versus standard dosing practices in patients with heart failure. Pharmacotherapy. 2014;34:1121–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Cheng JW, Charland SL, Shaw LM, et al. Is the volume of distribution of digoxin reduced in patients with renal dysfunction? Determining digoxin pharmacokinetics by fluorescence polarization immunoassay. Pharmacotherapy. 1997;17:584–90.

    CAS  PubMed  Google Scholar 

  30. Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med. 1993;329:1–7.

    Article  CAS  PubMed  Google Scholar 

  31. Gheorghiade M, Patel K, Filippatos G, et al. Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail. 2013;15:551–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Bourge RC, Fleg JL, Fonarow GC, et al. Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am J Med. 2013;126:701–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Testani JM, Brisco MA, Tang WH, et al. Potential effects of digoxin on long-term renal and clinical outcomes in chronic heart failure. J Card Fail. 2013;19:295–302.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Ather S, Peterson LE, Divakaran VG, et al. Digoxin treatment in heart failure—unveiling risk by cluster analysis of DIG data. Int J Cardiol. 2011;150:264–9.

    Article  PubMed  Google Scholar 

  35. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med. 2002;347:1403–11.

    Article  CAS  PubMed  Google Scholar 

  36. Adams Jr KF, Patterson JH, Gattis WA, et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol. 2005;46:497–504.

    Article  CAS  PubMed  Google Scholar 

  37. Domanski M, Fleg J, Bristow M, Knox S. The effect of gender on outcome in digitalis-treated heart failure patients. J Card Fail. 2005;11:83–6.

    Article  CAS  PubMed  Google Scholar 

  38. Dhaliwal AS, Bredikis A, Habib G, Carabello BA, Ramasubbu K, Bozkurt B. Digoxin and clinical outcomes in systolic heart failure patients on contemporary background heart failure therapy. Am J Cardiol. 2008;102:1356–60.

    Article  CAS  PubMed  Google Scholar 

  39. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–75.

    Article  CAS  PubMed  Google Scholar 

  40. Butler J, Anand IS, Kuskowski MA, et al. Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT). Congest Heart Fail. 2010;16:191–5.

    Article  PubMed  Google Scholar 

  41. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–17.

    Article  CAS  PubMed  Google Scholar 

  42. Freeman JV, Yang J, Sung SH, Hlatky MA, Go AS. Effectiveness and safety of digoxin among contemporary adults with incident systolic heart failure. Circ Cardiovasc Qual Outcomes. 2013;6:525–33.

    Article  PubMed  Google Scholar 

  43. Ahmed A, Bourge RC, Fonarow GC, et al. Digoxin use and lower 30-day all-cause readmission for Medicare beneficiaries hospitalized for heart failure. Am J Med. 2014;127:61–70.

    Article  CAS  PubMed  Google Scholar 

  44. Georgiopoulou VV, Kalogeropoulos AP, Giamouzis G, et al. Digoxin therapy does not improve outcomes in patients with advanced heart failure on contemporary medical therapy. Circ Heart Fail. 2009;2:90–7.

    Article  CAS  PubMed  Google Scholar 

  45. Corley SD, Epstein AE, DiMarco JP, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation. 2004;109:1509–13.

    Article  PubMed  Google Scholar 

  46. Whitbeck MG, Charnigo RJ, Khairy P, et al. Increased mortality among patients taking digoxin—analysis from the AFFIRM study. Eur Heart J. 2013;34:1481–8.

    Article  CAS  PubMed  Google Scholar 

  47. Gheorghiade M, Fonarow GC, van Veldhuisen DJ, et al. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J. 2013;34:1489–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Behlouli H, Pilote L. Relation of digoxin use in atrial fibrillation and the risk of all-cause mortality in patients >/=65 years of age with versus without heart failure. Am J Cardiol. 2014;114:401–6.

    Article  CAS  PubMed  Google Scholar 

  49. Adelstein E, Schwartzman D, Jain S, Bazaz R, Saba S. Effect of digoxin on shocks in cardiac resynchronization therapy-defibrillator patients with coronary artery disease. Am J Cardiol. 2014;113:970–5.

    Article  CAS  PubMed  Google Scholar 

  50. Lee AY, Kutyifa V, Ruwald MH, et al. Digoxin therapy and associated clinical outcomes in the MADIT-CRT trial. Heart Rhythm. 2015;12:2010–7.

    Article  PubMed  Google Scholar 

  51. Vamos M, Erath JW, Hohnloser SH. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. Eur Heart J. 2015;36:1831–8.

    Article  PubMed  Google Scholar 

  52. Ziff OJ, Lane DA, Samra M, et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ. 2015;351:h4451.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Patel N, Ju C, Macon C, et al. Temporal trends of Digoxin use in patients hospitalized with heart failure: analysis from the American heart association get with the guidelines-heart failure registry. JACC Heart Fail. 2016;4:348–56.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH, 44195, USA

    Chonyang L. Albert, Forum Kamdar & Mazen Hanna

Authors
  1. Chonyang L. Albert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Forum Kamdar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mazen Hanna
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mazen Hanna.

Ethics declarations

Conflict of Interest

Chonyang L. Albert, Forum Kamdar, and Mazen Hanna declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Chonyang L. Albert and Forum Kamdar are both co-first authors.

Mazen Hanna is the senior author.

This article is part of the Topical Collection on Pharmacologic Therapy

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Albert, C.L., Kamdar, F. & Hanna, M. Contemporary Controversies in Digoxin Use in Systolic Heart Failure. Curr Heart Fail Rep 13, 197–206 (2016). https://doi.org/10.1007/s11897-016-0302-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11897-016-0302-z

Keywords

Search

Navigation